Sheng-Xiang Rao
Overview
Explore the profile of Sheng-Xiang Rao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
82
Citations
1465
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huang X, Wu L, Xue C, Rao C, Fang Q, Chen Y, et al.
World J Hepatol
. 2024 Nov;
16(11):1290-1305.
PMID: 39606168
Background: Non-invasive methods to diagnose non-alcoholic steatohepatitis (NASH), an inflammatory subtype of non-alcoholic fatty liver disease (NAFLD), are currently unavailable. Aim: To develop an integrin αvβ3-targeted molecular imaging modality to...
2.
Abedrabbo N, Lerner E, Lam E, Kadi D, Dawit H, Van der Pol C, et al.
Abdom Radiol (NY)
. 2024 Sep;
PMID: 39333410
Background: The Liver Imaging Reporting and Data System (LI-RADS) does not consider factors extrinsic to the observation of interest, such as concurrent LR-5 observations. Purpose: To evaluate whether the presence...
3.
Chen Y, Yang L, Li J, Rao S, Ding Y, Zeng M
World J Hepatol
. 2024 Sep;
16(8):1167-1176.
PMID: 39221094
Background: Neoadjuvant chemotherapy can cause hepatic sinusoidal obstruction syndrome (SOS) in patients with colorectal cancer liver metastases and increases postoperative morbidity and mortality. Aim: To evaluate T mapping based on...
4.
Wang W, Wang Y, Song D, Zhou Y, Luo R, Ying S, et al.
Liver Int
. 2024 Jan;
44(4):894-906.
PMID: 38263714
Background & Aims: We aimed to develop a Transformer-based deep learning (DL) network for prognostic stratification in hepatocellular carcinoma (HCC) patients undergoing RFA. Methods: A Swin Transformer DL network was...
5.
Wang F, Zhang X, Tang L, Wu Q, Cai M, Li Y, et al.
Cancer Commun (Lond)
. 2023 Dec;
44(1):127-172.
PMID: 38160327
The 2023 update of the Chinese Society of Clinical Oncology (CSCO) Clinical Guidelines for Gastric Cancer focuses on standardizing cancer diagnosis and treatment in China, reflecting the latest advancements in...
6.
Wang J, Qiu Q, Dong S, Chen X, Wang W, Yang Y, et al.
Acta Radiol
. 2023 Sep;
64(10):2687-2696.
PMID: 37691270
Background: Biannual Ultrasound showed insufficient sensitivity in detecting small or early-stage hepatocellular carcinoma (HCC). Abbreviated magnetic resonance imaging (A-MRI) protocols with fewer sequences demonstrated higher HCC detection sensitivity than ultrasound...
7.
Shi X, Wang J, Rao S, Liu T, Wu H
Front Pharmacol
. 2023 Sep;
14:1246657.
PMID: 37663264
A number of patients with Crohn's disease (CD) suffer from loss of response to infliximab (IFX) therapy. Splenic volume is reported to be enlarged in patients with CD compared to...
8.
Xu B, Dong S, Bai X, Song T, Zhang B, Zhou L, et al.
Liver Cancer
. 2023 Aug;
12(3):262-276.
PMID: 37601982
Introduction: Lenvatinib plus an anti-PD-1 antibody has shown promising antitumor effects in patients with advanced hepatocellular carcinoma (HCC), but with clinical benefit limited to a subset of patients. We developed...
9.
Guo D, Zhang S, Dong S, Yan J, Wang Y, Cao Y, et al.
Front Immunol
. 2023 Mar;
14:1141199.
PMID: 36911686
Background: Lenvatinib monotherapy and combination therapy with immune checkpoint inhibitors (ICI) were widely applied for unresectable hepatocellular carcinoma (uHCC). However, many patients failed to benefit from the treatments. A prognostic...
10.
Guo D, Zhang S, Dong S, Yan J, Wang Y, Cao Y, et al.
Front Oncol
. 2023 Mar;
13:1109742.
PMID: 36910622
Background: Immune checkpoint inhibitor (ICI)-based combination therapy has opened a new avenue for the treatment of multiple malignancies including hepatocellular carcinoma (HCC). However, considering the unsatisfactory efficacy, biomarkers are urgently...